Li Tianhang, Wu Qian, Chen Yonggang, Zou Jili, Zhang Enjing
Tongren Hospital of Wuhan University (Wuhan Third Hospital), Wuhan University of Science and Technology, Wuhan, China.
Evid Based Complement Alternat Med. 2022 Oct 13;2022:1773616. doi: 10.1155/2022/1773616. eCollection 2022.
To evaluate the efficacy and safety of Shengxuening combined with conventional iron supplementation in the treatment of anemia during pregnancy.
Electronic searches of Embase, Web of Science, Cochrane Library, China Biomedical Literature Database (CBM), China Knowledge Network (CNKI), Wanfang database (Wanfang), and China Science and Technology Journal Database (VIP) were conducted. A randomized controlled trial of Shengxuening combined with conventional iron supplements for the treatment of anemia in pregnancy was included. The quality of the included trials was assessed using the Cochrane Handbook's Risk of Bias Assessment Tool (version 5.1.0), and data analysis was performed using RevMan 5.4 software and Stata 15.0 statistical software.
A total of 150 studies were detected and 17 studies with a total of 1741 cases were finally included. Meta-analysis results showed that the effectiveness of Shengxuening combined with conventional iron supplementation was significantly better than that of conventional iron supplementation alone, and the adverse effects were significantly reduced compared with that of iron supplementation alone, and various anemia indicators such as Hb, RBC, MCV, and MCHC and iron metabolism indicators such as SI and TSAT were also significantly increased.
The efficacy of the combination of Shengxuening and conventional iron supplementation in the treatment of anemia in pregnancy is better than that of conventional iron supplementation alone, and the adverse effects in the experimental group are much less than those in the control group, but the quality of the included studies is not high, and more high-quality randomized controlled trials are needed for further validation.
评估生血宁联合传统补铁疗法治疗妊娠期贫血的疗效及安全性。
检索Embase、Web of Science、Cochrane图书馆、中国生物医学文献数据库（CBM）、中国知网（CNKI）、万方数据库（万方）和中国科技期刊数据库（维普）。纳入生血宁联合传统铁剂治疗妊娠期贫血的随机对照试验。采用Cochrane手册的偏倚风险评估工具（5.1.0版）评估纳入试验的质量，并使用RevMan 5.4软件和Stata 15.0统计软件进行数据分析。
共检索到150项研究，最终纳入17项研究，共1741例。Meta分析结果显示，生血宁联合传统补铁疗法的疗效显著优于单纯传统补铁疗法，不良反应较单纯补铁疗法显著减少，血红蛋白（Hb）、红细胞（RBC）、平均红细胞体积（MCV）、平均红细胞血红蛋白浓度（MCHC）等各项贫血指标以及血清铁（SI）、转铁蛋白饱和度（TSAT）等铁代谢指标也显著升高。
生血宁联合传统补铁疗法治疗妊娠期贫血的疗效优于单纯传统补铁疗法，试验组不良反应远少于对照组，但纳入研究质量不高，需要更多高质量随机对照试验进一步验证。
